Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea.
Department of Pathology, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea.
Oncology. 2024;102(11):969-978. doi: 10.1159/000540521. Epub 2024 Jul 25.
Reactive oxygen species modulator 1 (Romo1) is a novel protein that is critically involved in the intracellular production of reactive oxygen species. Evidence has revealed that Romo1 is associated with treatment outcomes of various human malignancies, including lung cancer. However, the clinical implications of this protein in surgically resected lung cancers harboring epidermal growth factor receptor (EGFR) mutations have not been investigated.
Data were collected from patients who underwent curative resection of EGFR-mutant lung adenocarcinoma. Romo1 protein expression levels were measured in the tumor tissue using immunohistochemical staining and evaluated semi-quantitatively using the histochemical score. Univariate and multivariate analyses were performed to identify the clinicopathological parameters that may be associated with clinical outcomes.
A total of 98 samples were analyzed. Using the cutoff H score of 200, the population was classified into low (n = 73) and high (n = 25) Romo1 groups. Romo1 expression was significantly higher in smokers, patients with stage III disease, and patients who experienced recurrence after surgery (all p < 0.05). Multivariate analyses showed that advanced-stage and poorly differentiated cancers were associated with shorter disease-free survival (DFS). In addition, high Romo1 expression was independently associated with poor DFS (hazard ratio = 2.18, 95% confidence interval: 1.10-4.32, p = 0.0261).
Our data showed that Romo1 overexpression was significantly associated with early recurrence in patients with resected EGFR-mutant lung adenocarcinoma. Although large-scale studies are required, Romo1 may play a prognostic role in this patient population.
活性氧物种调节剂 1（Romo1）是一种新型蛋白质，在细胞内活性氧的产生中起着关键作用。有证据表明，Romo1 与各种人类恶性肿瘤（包括肺癌）的治疗结果有关。然而，尚未研究该蛋白在表皮生长因子受体（EGFR）突变的手术切除肺癌中的临床意义。
从接受 EGFR 突变型肺腺癌根治性切除术的患者中收集数据。使用免疫组织化学染色法测量肿瘤组织中的 Romo1 蛋白表达水平，并使用组织化学评分进行半定量评估。进行单变量和多变量分析，以确定可能与临床结果相关的临床病理参数。
共分析了 98 例样本。使用 H 评分的截断值 200，将人群分为 Romo1 低表达组（n=73）和 Romo1 高表达组（n=25）。Romo1 表达在吸烟者、III 期疾病患者和手术后复发患者中明显更高（均 p<0.05）。多变量分析显示，晚期和低分化癌症与无病生存期（DFS）较短相关。此外，Romo1 高表达与较差的 DFS 独立相关（风险比=2.18，95%置信区间：1.10-4.32，p=0.0261）。
我们的数据表明，Romo1 过表达与切除的 EGFR 突变型肺腺癌患者的早期复发显著相关。尽管需要进行大规模研究，但 Romo1 可能在该患者群体中具有预后作用。
